EGFR

EGFR (Epidermal Growth Factor Receptor) appears in the context of Cytospire's CYT X300 pan-gamma delta T cell engager programme, funded by a £61m Series A in May 2026. EGFR is a validated solid tumour target; the reference indicates that CYT X300 is being developed against EGFR-expressing tumour cells, connecting the pan-gamma delta mechanism to an established oncology target.

EGFR is a transmembrane receptor tyrosine kinase involved in cell growth and differentiation. Mutations or overexpression of EGFR are common in non-small cell lung cancer (NSCLC), colorectal cancer, head and neck squamous cell carcinoma, and glioblastoma. EGFR has been a major pharmaceutical target for over two decades, with approved therapies including gefitinib (Iressa), erlotinib (Tarceva), and osimertinib (Tagrisso). Resistance to EGFR inhibitors is a key clinical challenge, driving interest in alternative mechanisms like gamma delta T cell engagement to target EGFR-expressing tumours through immune activation rather than direct kinase inhibition.